Company Overview and News

0
QCP / Quality Care Properties, Inc. DEFA14A

2018-07-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
QCP

0
QCP / Quality Care Properties, Inc. DEFA14A

2018-07-03 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
QCP

0
QCP / Quality Care Properties, Inc. DEFA14A

2018-07-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
QCP

0
QCP / Quality Care Properties, Inc. DEFA14A

2018-06-21 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
QCP

7
Healthcare REITs: Back From The Dead?

2018-06-21 seekingalpha
Amid fears of rising rates and deteriorating fundamentals, healthcare REITs were left for dead. Since early March, however, the sector has sprung back to life, jumping nearly 15%.
VTR DOC HR HTA WELL QCP

0
QCP / Quality Care Properties, Inc. DEFM14A

2018-06-21 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
QCP

47
Savara started at outperform with $40 stock price target at Evercore ISI

2018-06-08 marketwatch
Lyon Street Capital, LLC Buys Strongbridge Biopharma PLC, Recro Pharma Inc, Stemline Therapeutics Inc, Sells Natus Medical Inc, GTT Communications Inc, Concert Pharmaceuticals Inc
WST PEB.PRC CNCE MRDND STML QCP REPH GTT ATIS PEB.PRD SVRA MRDN PEB

0
QCP / Quality Care Properties, Inc. PREM14A

2018-06-06 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
QCP

11
Tax reform leads to question: To be or not to be a REIT?

2018-06-05 investmentnews
A quarterly report on the trends and ideas that advisers who serve retirement plan sponsors and participants care about.
VNO.PRICL VNO.WI VNORP NCT QCP SRG.PRA MAC NCT.WI VNO.PRH VNO.PRK VNO.PRF VNO.PRL VNO.PRM VNO DS NCT.PRB NCT.PRC NCT.PRD SRG JBGS DS.PRC DS.PRB DS.PRD VNO.PRG VNO.PRI

0
QCP / Quality Care Properties, Inc. / Falcon Edge Capital LP - 13G (Passive Investment)

2018-05-29 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
QCP

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

4h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

CUSIP: 747545101